Quick Answer
Milestone Pharmaceuticals Inc. reported Net Income of -$63.06 million for fiscal year 2025.
Milestone Pharmaceuticals Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$63.06M -51.9% |
-$41.52M +30.4% |
-$59.69M -2.2% |
-$58.39M -36.3% |
-$42.85M +14.2% |
-$49.97M +9.5% |
| Diluted EPS | -$0.75 -11.9% |
-$0.67 +51.8% |
-$1.39 -0.7% |
-$1.38 -35.3% |
-$1.02 +40.0% |
-$1.70 |
| Total Assets | $113.56M +50.4% |
$75.50M +0.4% |
$75.23M +1.0% |
$74.48M -37.9% |
$119.85M -20.1% |
$149.97M +21.5% |
| Cash and Equivalents | $73.05M +188.6% |
$25.31M +84.0% |
$13.76M +80.2% |
$7.64M -93.3% |
$114.14M +57.8% |
$72.31M -39.7% |
| Long-Term Debt | $57.19M +7.2% |
$53.35M +7.2% |
$49.77M | — | — | — |
| Stockholders Equity | $41.77M +217.7% |
$13.15M -21.6% |
$16.77M -74.7% |
$66.35M -41.1% |
$112.60M -21.3% |
$143.12M +24.5% |
| R&D Expense | $18.11M +26.1% |
$14.36M -53.8% |
$31.05M -22.0% |
$39.83M +3.0% |
$38.67M +12.1% |
$34.49M -17.9% |
| Operating Income | -$62.14M -47.6% |
-$42.10M +31.1% |
-$61.10M -2.4% |
-$59.64M -38.5% |
-$43.07M +15.1% |
-$50.71M +12.4% |
| Shares Outstanding | 106.24M +99.1% |
53.35M +59.3% |
33.48M -2.3% |
34.29M +14.7% |
29.90M +0.2% |
29.83M +21.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$11.92M | -26.3% | +8.1% |
| Diluted EPS | September 30, 2025 | -$0.12 | +14.3% | +40.0% |
| Total Assets | September 30, 2025 | $87.75M | +6.1% | +85.1% |
| Cash and Equivalents | September 30, 2025 | $46.69M | +264.8% | +9.8% |
| Long-Term Debt | September 30, 2025 | $56.21M | +7.2% | +1.8% |
| Stockholders Equity | September 30, 2025 | $20.50M | -14.6% | +215.5% |
| R&D Expense | September 30, 2025 | $3.94M | -0.6% | +7.4% |
| Operating Income | September 30, 2025 | -$11.83M | -23.0% | +5.6% |
| Shares Outstanding | September 30, 2025 | 85.17M | +59.7% | +59.2% |
- Milestone Pharmaceuticals Inc. reported Net Income of -$63.06 million for fiscal year 2025.
- Milestone Pharmaceuticals Inc. showed a decrease of -51.9% in Net Income compared to the prior fiscal year.
- Milestone Pharmaceuticals Inc. reported Diluted EPS of $0.75 per share (loss) for fiscal year 2025.
- Milestone Pharmaceuticals Inc. showed a decrease of -11.9% in Diluted EPS compared to the prior fiscal year.
- Milestone Pharmaceuticals Inc. reported Total Assets of $113.56 million for fiscal year 2025.
- Milestone Pharmaceuticals Inc. showed an increase of +50.4% in Total Assets compared to the prior fiscal year.
- Milestone Pharmaceuticals Inc. reported Cash and Equivalents of $73.05 million for fiscal year 2025.
- Milestone Pharmaceuticals Inc. showed an increase of +188.6% in Cash and Equivalents compared to the prior fiscal year.
- Milestone Pharmaceuticals Inc. reported Long-Term Debt of $57.19 million for fiscal year 2025.
- Milestone Pharmaceuticals Inc. showed an increase of +7.2% in Long-Term Debt compared to the prior fiscal year.
- Milestone Pharmaceuticals Inc. reported Stockholders Equity of $41.77 million for fiscal year 2025.
- Milestone Pharmaceuticals Inc. showed an increase of +217.7% in Stockholders Equity compared to the prior fiscal year.
- Milestone Pharmaceuticals Inc. reported R&D Expense of $18.11 million for fiscal year 2025.
- Milestone Pharmaceuticals Inc. showed an increase of +26.1% in R&D Expense compared to the prior fiscal year.
- Milestone Pharmaceuticals Inc. reported Operating Income of -$62.14 million for fiscal year 2025.
- Milestone Pharmaceuticals Inc. showed a decrease of -47.6% in Operating Income compared to the prior fiscal year.
- Milestone Pharmaceuticals Inc. reported Shares Outstanding of 106.24 million shares for fiscal year 2025.
- Milestone Pharmaceuticals Inc. showed an increase of +99.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: